Tiger BioSciences today highlights a year of pivotal progress across its clinical programs and scientific initiatives, driven by a renewed emphasis on evidence-based research and strategic investments in 2025. The company’s leadership says the expanded funding and collaborative approach have accelerated the translation of laboratory insights into patient-centered outcomes, reinforcing its position at the forefront…